TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up [Yahoo! Finance]
Alvotech (ALVO)
Company Research
Source: Yahoo! Finance
Earnings rose 20% year over year on a reported basis and 18% on a constant currency basis. Revenues for the first quarter came in at $3.82 billion, which beat the Zacks Consensus Estimate of $3.7 billion. Total revenues rose 4% on a reported basis and 5% on a constant currency basis. Sales growth was mainly driven by higher revenues from generic products globally and the branded drug Austedo. Revenue growth was partially offset by lower revenues from the Anda distribution business in the United States segment and lower sales of Copaxone. Segment Discussion Sales in the United States segment (previously the North America segment) were $1.73 billion, up 3% year over year, driven by higher sales of generic products and Austedo and Ajovy. The uptick was partially offset by lower sales of certain legacy brands like Copaxone, Bendeka/Treanda and Anda. United States revenues missed the Zacks Consensus Estimate of $1.77 billion as well as our model estimate of $1.78 billion. Generic
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar [Yahoo! Finance]Yahoo! Finance
- Alvotech GAAP EPS of -$0.89, revenue of $12.43M; raises FY24 topline revenue guidance [Seeking Alpha]Seeking Alpha
- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business UpdateGlobeNewswire
- Alvotech and Dr. Reddy's collaborate for commercialization of denosumab [Seeking Alpha]Seeking Alpha
ALVO
Earnings
- 5/21/24 - Miss
ALVO
Sec Filings
- 5/22/24 - Form 6-K
- 5/21/24 - Form 6-K
- 5/21/24 - Form 6-K
- ALVO's page on the SEC website